BioVie (BIVI)
NASDAQ:BIVI
Want to see BIVI full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Strong Equity Position
A strong equity position with minimal debt provides financial stability, allowing BioVie to fund R&D activities without immediate pressure from creditors.
Negative Factors
High Cash Burn
High cash burn without revenue generation can strain financial resources, necessitating continuous external financing, which may dilute shareholder value over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Equity Position
A strong equity position with minimal debt provides financial stability, allowing BioVie to fund R&D activities without immediate pressure from creditors.
Read all positive factors
BioVie (BIVI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.88M
Dividend YieldN/A
Average Volume (3M)240.84K
Price to Earnings (P/E)―
Beta (1Y)1.78
Revenue GrowthN/A
EPS Growth79.70%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.47
Shares Outstanding7,541,839
10 Day Avg. Volume205,264
30 Day Avg. Volume240,835
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.10
Enterprise Value/Ebitda0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
BioVie Business Overview & Revenue Model
Company Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the tr...
How the Company Makes Money
BioVie primarily makes money through the development and eventual commercialization of its pharmaceutical products. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and...
BioVie Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229.38K | -229.38K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -20.01M | -17.84M | -31.95M | -45.73M | -27.02M | -137.82M |
| Net Income | -19.92M | -17.54M | -32.12M | -50.26M | -26.08M | -130.25M |
Balance Sheet | ||||||
| Total Assets | 17.51M | 21.56M | 25.21M | 35.10M | 20.11M | 6.05M |
| Cash, Cash Equivalents and Short-Term Investments | 13.10M | 17.54M | 23.84M | 33.94M | 18.64M | 4.51M |
| Total Debt | 295.72K | 349.89K | 6.11M | 14.42M | 12.26M | 0.00 |
| Total Liabilities | 1.91M | 2.55M | 9.70M | 19.76M | 16.44M | 996.37K |
| Stockholders Equity | 15.61M | 19.01M | 15.51M | 15.34M | 3.67M | 5.05M |
Cash Flow | ||||||
| Free Cash Flow | -20.51M | -19.03M | -27.95M | -40.25M | -18.99M | -10.45M |
| Operating Cash Flow | -20.51M | -19.03M | -27.95M | -40.25M | -18.99M | -10.45M |
| Investing Cash Flow | 0.00 | 0.00 | 14.53M | -14.30M | 0.00 | 0.00 |
| Financing Cash Flow | 10.46M | 12.73M | 17.80M | 55.37M | 33.12M | 14.93M |
BioVie Technical Analysis
Positive
1.56
Price Trends
1.34
Positive
1.34
Positive
2.24
Negative
Market Momentum
0.04
Negative
61.58
Neutral
69.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIVI, the sentiment is Positive. The current price of 1.56 is above the 20-day moving average (MA) of 1.39, above the 50-day MA of 1.34, and below the 200-day MA of 2.24, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 61.58 is Neutral, neither overbought nor oversold. The STOCH value of 69.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIVI.
BioVie Risk Analysis
BioVie disclosed 49 risk factors in its most recent earnings report. BioVie reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioVie Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $9.88M | -0.50 | -94.79% | ― | ― | 79.70% | |
59 Neutral | $116.04M | -2.56 | -82.34% | ― | ― | 16.07% | |
47 Neutral | $60.67M | -1.63 | -197.72% | ― | ― | 58.01% | |
44 Neutral | $18.63M | -3.70 | -59.29% | ― | -45.52% | -94.82% | |
41 Neutral | $7.62M | ― | ― | ― | ― | ― |
* Healthcare Sector Average
BIVI
BioVie
1.31
-9.39
-87.76%
CANF
Can-Fite BioPharma
3.36
-17.54
-83.92%
LPCN
Lipocine
2.26
-1.37
-37.74%
EDSA
Edesa Biotech
13.05
11.04
549.25%
CING
Cingulate Inc
4.57
0.76
19.95%
BioVie Corporate Events
Executive/Board ChangesShareholder Meetings
BioVie Stockholders Approve Key Proposals at Annual Meeting
Neutral
Nov 12, 2025
On November 10, 2025, BioVie Inc. held its annual meeting of stockholders, where several key proposals were considered. Stockholders elected the company’s nominees for director for one-year terms, ratified the appointment of EisnerAmper LLP ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―